Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

An overview of the RSV vaccine landscape: GSK aims to extend its approval of Arexvy?

By Brian Buntz | October 30, 2023

Illustration of Respiratory Syncytial Virus or RSV

[Peter Hansen/Adobe Stock]

GSK (NYSE:GSK) is aiming to expand the label for its respiratory syncytial virus (RSV) vaccine Arexvy, which was the first to win FDA approval. The firm is now eyeing an extension of the label to include adults aged 50 to 59, bolstered by encouraging preliminary data from a phase 3 study.

The recent data from GSK’s phase 3 trial, NCT05590403,  revealed that Arexvy elicited a non-inferior immune response in adults aged 50 to 59 compared to those aged 60 and older, meeting the trial’s primary endpoints. If the findings bear out in the final analysis, GSK could possibly win a label expansion in 2024.

The initial FDA approval of the GSK vaccine targets adults aged 60 and older. In clinical studies, the single-dose vaccine demonstrated strong efficacy in preventing lower-respiratory tract infections and more severe diseases. In a phase 3 study published in NEJM with a median follow-up of 6.7 months, the vaccine efficacy against RT-PCR-confirmed RSV-related lower respiratory tract disease was 82.6%.

Efficacy against severe RSV-related lower respiratory tract disease was higher at 94.1% while efficacy against RSV-related acute respiratory infection was 71.7%. The most commonly reported side effects of Arexvy were injection site pain, fatigue, muscle pain, headache and joint stiffness/pain.

GSK reported a few cases of atrial fibrillation, acute disseminated encephalomyelitis (ADEM) and Guillain-Barré syndrome in trial participants. The FDA is requiring a postmarketing study to gauge the risks for ADEM and Guillain-Barré syndrome.

Other RSV vaccine competitors

Following GSK’s FDA approval of Arexvy, other drug developers have also made strides in the RSV vaccine landscape. On May 31, 2023, Pfizer scored FDA approval for its RSV bivalent vaccine, Abrysvo, designed to protect adults aged 60 and older. On August 21, 2023, FDA later extended the approval to pregnant women in their 32nd to 36th week of gestation, aiming to protect newborns from RSV during the crucial first six months of life. Abrysvo demonstrated a protection rate of 66.7% against RSV and 85.7% effectiveness against severe disease in the RENOIR trial.

In the phase 3 RENOIR trial, Abrysvo demonstrated a protection rate of 66.7% against RSV and 85.7% effectiveness against severe disease​.

Moderna, on the other hand, is advancing with its mRNA-1345 vaccine. The latest data reveals an 83.7% efficacy against RSV lower respiratory tract disease in older adults, and the vaccine is well-tolerated with no safety concerns. Moderna has initiated the regulatory submission process globally.

The CDC has also recommended AstraZeneca’s Nirsevimab for the protection of babies and toddlers, marking a significant stride to curb RSV-related hospitalizations and fatalities in this vulnerable age group.

The RSV vaccine market could ultimately be worth more than $10 billion, with GSK, Pfizer and Moderna poised to be early leaders.

The following table provides an update of the RSV vaccine landscape, including the current clinical trial phases and relevant notes about their efficacy and target populations. Janssen has halted its RSV development plans while Novavax has paused theirs.

Company Vaccine Candidate Clinical Trial Phase Notes
Moderna mRNA-1345 Phase 3 83.7% efficacy against RSV-LRTD in older adults, well-tolerated with no safety concerns​​.
GSK Arexvy (GSK3844766A) FDA approved For individuals aged 60 and above, the efficacy rate of preventing lower respiratory tract disease is 82.6%.
Pfizer Abrysvo FDA approved FDA approved for individuals aged 60 and older on May 31, 2023, and for pregnant women on August 21, 2023. Demonstrated a protection rate of 66.7% against RSV and 85.7% effectiveness against severe disease in the RENOIR trial​​.
Pfizer RSVpreF Phase 3 Found to be 81.8% effective against severe medically attended lower respiratory tract illness caused by RSV in infants from birth to 90 days old, with a 69.4% efficacy rate during the first six months of life. FDA is set to decide on approval in 2023.
Sanofi SP0274 Phase 1/2 Underway. Focus is on adults 18 to 50 old in a sentinel cohort and 60 years and older in main and booster cohorts.
Sanofi & AstraZeneca Nirsevimab (Beyfortus) Recommended by CDC Monoclonal antibody designed to provide passive immunity to infants, recently recommended by the CDC for use in infants to protect against RSV​​.

 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: Arexvy, FDA approval, GSK, Moderna, Pfizer, respiratory syncytial virus, RSV vaccine, RSV vaccine landscape
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Close-up medical syringe with a vaccine.
Six leading medical organizations sue RFK Jr. over vaccine recommendations
RFK’s new ACIP changed longstanding vaccine recommendations
Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE